The Chimeric Antigen Receptor (CAR)-T Cell Therapy was introduced by Max Healthcare on Tuesday. It is a state-of-the-art treatment for particular tumours, and all of its hospitals in Delhi-NCR will offer it.
In CAR-T treatment, immune cells from the patient are genetically modified in a lab to enable them to combat cancer. T cells, a subset of white blood cells with the ability to specifically target and eliminate cancer cells, are altered in the lab as part of the treatment.
The source of CAR T cells for this treatment is an IIT Bombay-incubated firm called ImmunoACT. ImmunoACT was granted marketing authorization approval by the Central Drugs Standard Control Organisation (CDSO) last month for its CAR-T cell therapy product, which is intended to treat leukaemia and relapsed/refractory B-cell lymphomas in India.
Often referred to as a “living drug,” this treatment offers long-lasting advantages and is suggested for individuals unable to receive a stem cell transplant or experiencing a relapse following a transplant. With an average of two weeks of in-patient care, this requires a brief, single-infusion treatment, compared to standard therapy, and the doctors reported that this improved the quality of life for many patients.Patients in India and countries with limited resources will now have access to this life-saving drug at an affordable cost.
